vasopressin (AVP): the endogenous nine-residue peptide hormone

vasopressin (AVP), also called arginine vasopressin or antidiuretic hormone (ADH), is a nine-amino-acid peptide hormone made by neurons in the hypothalamus and released from the posterior pituitary. peripherally it conserves water at the kidney and raises vascular tone. centrally it acts on the stress axis and on circuits that shape social behavior. it is one half of the vasopressin-oxytocin nonapeptide family that has anchored neuropeptide research for nearly a century.

what is vasopressin?

vasopressin is a cyclic nonapeptide synthesized in magnocellular neurons of the paraventricular and supraoptic nuclei of the hypothalamus. it is packaged with its carrier protein neurophysin II, transported down the axon to the posterior pituitary, and released into the bloodstream in response to rising plasma osmolality or falling blood volume.

the molecule has a six-residue ring closed by a disulfide bridge between two cysteine residues, with a three-residue tail. that compact ring-and-tail structure is shared with oxytocin, its evolutionary paralog, which differs by only two amino acids [1]. the gene encoding AVP sits adjacent to the oxytocin gene on chromosome 20 in humans, and the two are believed to have arisen from a single ancestral nonapeptide gene roughly 600 million years ago. vasopressin is sometimes referred to in the clinical literature as ADH; both names refer to the same molecule.

the principal physiological trigger for AVP release is a rise in plasma osmolality, sensed by osmoreceptors in the organum vasculosum of the lamina terminalis. a secondary trigger is a fall in effective circulating volume, sensed by baroreceptors in the carotid sinus and aortic arch. these two inputs sit at the top of the renin-angiotensin-aldosterone system and the broader fluid-balance network that defines a large part of human physiology.

how does it work?

vasopressin signals through three G protein-coupled receptors: V1a in vascular smooth muscle, liver, and the brain; V1b in the anterior pituitary; and V2 in the renal collecting duct. each receptor couples to a different intracellular cascade and a different physiologic effect.

V2 receptors on the basolateral membrane of collecting duct principal cells couple to G-alpha-s and raise intracellular cAMP, which drives trafficking of aquaporin-2 water channels to the apical membrane. the result is increased water permeability of the collecting duct and reabsorption of free water, the antidiuretic effect that gives the hormone its alternate name [2]. loss of V2 signaling, whether through AVP deficiency or aquaporin-2 mutation, produces central or nephrogenic diabetes insipidus respectively.

V1a receptors on vascular smooth muscle couple to G-alpha-q and raise intracellular calcium, producing vasoconstriction. that pressor activity is the basis for AVP's use as a vasopressor in vasodilatory shock. central V1a receptors in regions like the lateral septum, amygdala, and ventral pallidum are the substrate for the behavioral effects that have made AVP a focus of social neuroscience [3]. V1b receptors (sometimes called V3) sit on corticotrophs in the anterior pituitary and synergize with corticotropin-releasing hormone to drive ACTH release, anchoring AVP into the HPA stress axis.

what does the evidence show?

the clinical evidence is strongest for two peripheral indications: vasopressin as a catecholamine-sparing vasopressor in septic and vasodilatory shock, and as a treatment for central diabetes insipidus when desmopressin is not appropriate. the behavioral evidence centers on a large rodent literature (especially in prairie voles) on pair bonding and a smaller human literature on intranasal AVP and social cognition.

the VASST trial, published by Russell and colleagues in the New England Journal of Medicine in 2008, compared low-dose vasopressin against norepinephrine in 778 patients with septic shock and found no significant difference in 28-day mortality overall, with a possible benefit in the less severe subgroup [4]. the follow-up VANISH trial, by Gordon and colleagues in JAMA in 2016, randomized patients with septic shock to vasopressin or norepinephrine as first-line therapy and again found no difference in kidney failure-free days [5]. the practical takeaway is that AVP is a useful catecholamine-sparing option in shock, not a mortality-improving substitute.

in social neuroscience the foundational work is Young and Wang's prairie vole research, which demonstrated that V1a receptor distribution in the ventral pallidum is the key molecular difference between monogamous and non-monogamous vole species and that viral overexpression of V1a in the ventral pallidum is sufficient to drive partner preference [3]. in humans, small intranasal AVP studies have reported modest effects on emotion recognition, social communication, and aggression-related responses, but the literature is small, heterogeneous, and at risk of publication bias. a recent randomized trial of intranasal AVP in autism reported improved social ability scores in a small pediatric sample, which the authors framed as proof of concept rather than a treatment recommendation [6].

regulatory status

synthetic vasopressin is FDA-approved as a prescription drug for central diabetes insipidus, for prevention and treatment of postoperative abdominal distension, and as a vasopressor for adults with vasodilatory shock who remain hypotensive despite fluids and other vasopressors. it is not approved for cognitive or behavioral use. the World Anti-Doping Agency prohibits vasopressin and its analogs.

Vasostrict, the first FDA-approved formulation of vasopressin, was approved in 2014 after the agency reclassified the long-marketed unapproved product under its Unapproved Drugs Initiative. the approved indication is increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and other vasopressors. additional historical indications include diabetes insipidus and prevention of postoperative abdominal distension. Vasostrict and its generics are the formulations used in US hospitals.

the World Anti-Doping Agency lists vasopressin and its agonists under category S5 (diuretics and masking agents) because of their effect on urine concentration and the potential to mask other prohibited substances. intranasal vasopressin for behavioral or cognitive purposes is not FDA-approved, and supplies marketed outside that framework are research-use-only material.

safety profile and side effects

the dominant safety concerns with AVP reflect its pharmacology: water retention with risk of hyponatremia at the kidney, and vasoconstriction with risk of ischemia at the vasculature. central and intranasal use raises additional questions about CNS penetration and downstream effects on the stress axis.

hyponatremia is the most clinically important adverse event in any therapy that mimics AVP. excessive V2 receptor activation in the collecting duct produces water reabsorption out of proportion to sodium and dilutes plasma sodium, which in severe cases can cause seizures and cerebral edema [2]. the same mechanism explains the syndrome of inappropriate antidiuretic hormone secretion (SIADH), in which endogenous AVP is dysregulated.

vasoconstrictive adverse events of intravenous AVP include peripheral ischemia, mesenteric ischemia, and cardiac ischemia, and these scale with infusion intensity. the VASST and VANISH trials reported similar overall adverse event rates between AVP and norepinephrine arms but a different distribution of organ-specific complications, which is what one would expect from two vasopressors with different receptor selectivity [4][5].

for intranasal AVP used in behavioral studies, short-term tolerability has generally been reported as good with mild and transient effects, but the duration and sample size of the existing trials do not support strong long-term safety claims. AVP also engages the V1b receptor on the anterior pituitary and can modulate ACTH and cortisol release, which is a real but underappreciated reason to interpret behavioral studies cautiously.

where it fits in peptide therapy

vasopressin is best understood as an endogenous hormone whose therapeutic descendants split along receptor selectivity. desmopressin selectively activates V2 and is the standard antidiuretic. selective V2 antagonists like tolvaptan block water reabsorption and are used for hyponatremia and polycystic kidney disease. selective V1a antagonists have been explored for behavioral indications. the parent molecule itself remains a vasopressor and a rescue antidiuretic.

desmopressin (DDAVP) is the most familiar derivative. two structural changes, D-arginine substitution at position 8 and removal of the N-terminal amino group, strip away vasoconstrictor activity and extend half-life enough for outpatient use. it is the standard therapy for central diabetes insipidus, primary nocturnal enuresis, and certain bleeding disorders. the prescribing label is precise and the drug is widely available.

the closely related neuropeptide is oxytocin, the other half of the nonapeptide family. the two molecules differ by only two amino acids, share receptor cross-reactivity, and are frequently studied as a paired system in social neuroscience. the AVP literature is best read alongside the oxytocin literature for that reason.

for a broader map of how endogenous peptide hormones sit alongside the engineered peptides used in current research, the underlying biology is covered in our free peptides and your body module, and the FDA-approved peptide landscape including AVP is summarized in our peptide approval guide.